Trial · NCT07906262
Efficacy of Rimegepant 75 mg for the Acute Treatment of Migraine: a Bayesian Individual Participant Data Meta-analysis Standardized to Defined Target Populations
NCT07906262, Active not recruiting, Pfizer
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of Rimegepant 75 mg for the Acute Treatment of Migraine: a Bayesian Individual Participant Data Meta-analysis Standardized to Defined Target Populations. Trials, record NCT07906262. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07906262
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of Rimegepant 75 mg for the Acute Treatment of Migraine: a Bayesian Individual Participant Data Meta-analysis Standardized to Defined Target Populations
- NCT number
- NCT07906262
- Status
- Active not recruiting
- Enrollment
- 1 participants, actual
- Lead sponsor
- Pfizer
- Conditions
- Migraine
- Interventions
- Rimegepant, Placebo
- First posted
- 2026-10-30
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pain Freedom at 2 Hours Postdose | 2 hours after administration of study treatment | Average treatment effect of rimegepant 75 mg relative to placebo on the proportion of participants who achieve pain freedom 2 hours after treatment of a moderate or severe migraine attack. |
| Primary | Freedom From the Most Bothersome Symptom at 2 Hours Postdose | 2 hours after administration of study treatment | Average treatment effect of rimegepant 75 mg relative to placebo on the proportion of participants who are free from their prespecified most bothersome migraine-associated symptom 2 hours after treatment. |
| Primary | Pain Relief at 2 Hours Postdose | 2 hours after administration of study treatment | Average treatment effect of rimegepant 75 mg relative to placebo on the proportion of participants achieving pain relief 2 hours after treatment of a moderate or severe migraine attack. |
| Secondary | Pain Freedom at 1 Hour Postdose | 1 hour after administration of study treatment | Average treatment effect of rimegepant 75 mg relative to placebo on the proportion of participants who achieve pain freedom 1 hour after treatment of a moderate or severe migraine attack. |
| Secondary | Pain Relief at 1 Hour Postdose | 1 hour after administration of study treatment | Average treatment effect of rimegepant 75 mg relative to placebo on the proportion of participants achieving pain relief 1 hour after treatment of a moderate or severe migraine attack. |
| Secondary | Return to Normal Function at 1 Hour Postdose | 1 hour after administration of study treatment | Average treatment effect of rimegepant 75 mg relative to placebo on the proportion of participants with normal function 1 hour after treatment. |
| Secondary | Return to Normal Function at 2 Hours Postdose | 2 hours after administration of study treatment | Average treatment effect of rimegepant 75 mg relative to placebo on the proportion of participants with normal function 2 hours after treatment. |
| Secondary | Sustained Pain Freedom From 2 to 24 Hours Postdose | 2 to 24 hours after administration of study treatment | Average treatment effect of rimegepant 75 mg relative to placebo on the proportion of participants with sustained pain freedom from 2 through 24 hours after treatment. |
| Secondary | Sustained Pain Freedom From 2 to 48 Hours Postdose | 2 to 48 hours after administration of study treatment | Average treatment effect of rimegepant 75 mg relative to placebo on the proportion of participants with sustained pain freedom from 2 through 48 hours after treatment. |
| Secondary | Sustained Pain Relief From 2 to 24 Hours Postdose | 2 to 24 hours after administration of study treatment | Average treatment effect of rimegepant 75 mg relative to placebo on the proportion of participants with sustained pain relief from 2 through 24 hours after treatment. |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07906262
GET https://conductscience.org/api/trials/v1/NCT07906262/registered